Aim: To develop a mobile app for education and screening regarding oral cancer in the general population.
Materials And Methods: A mobile app titled Prayaas-Oral Cancer Prevention, Treatment, and Rehabilitation was designed and developed to be installed on a basic mobile handset with or without internet. It was aimed for the common public, patients as well as healthcare providers. The contents included all information in the pictorial format as well as videos regarding oral cancer awareness, tobacco de-addiction, self-oral examination, various surgeries, and rehabilitation options. It was pilot tested in 50 factory workers of rural set-up. Participants' feedback was recorded using a self- report questionnaire.
Results: Overall feedback was very positive, they found the app easy to operate, enhancing knowledge regarding oral cancer and they recommended this to be used for the general population.
Conclusions: Within limitations of this pilot study, it can be inferred that mobile technology can be successfully used to reach out to bottom of the pyramid population residing in inaccessible rural population for creating public health issues such as oral cancer.
Clinical Significance: Oral cancer is preventable through risk factor intervention especially tobacco de-addiction. The self- oral examination can be a very critical factor in early diagnosis of oral cancer. Access to care is a major issue in our country owing to low levels of education, lower income and exposure to risk factors such as tobacco. The fact that today there is widespread use of mobile technology by people belonging to all socioeconomic groups can be harnessed for this public health awareness initiative. This app can be used as a tool for patient education for prevention as well as early detection of oral cancer, both of which can be key to reduce oral cancer morbidity and mortality in India.
Download full-text PDF |
Source |
---|
Arch Toxicol
January 2025
Department of Chemical and Product Safety, German Federal Institute for Risk Assessment (BfR), Berlin, Germany.
About one-fifth of people in industrialised countries are tattooed, potentially putting them at risk of exposure to possible carcinogenic or otherwise harmful substances. This study aims to determine the exposure to soluble tattoo ink ingredients and their excretion within 24 h after tattooing. In this clinical study, 24 subjects were tattooed with black or red tattoo ink to which the 3 tracer substances, potassium iodide, 4-aminobenzoic acid (PABA) and 2-phenoxyethanol (PEtOH), had been added to mimic known substances found in tattoo inks.
View Article and Find Full Text PDFNaunyn Schmiedebergs Arch Pharmacol
January 2025
Department of Pharmacognosy, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.
Non-small cell lung cancer (NSCLC) is a widespread highly malignant type of lung cancer. Conventional chemotherapeutic drugs may be accompanied by both drug resistance and serious side effects in patients. Therefore, safer and more effective medications are urgently needed for the treatment of NSCLC.
View Article and Find Full Text PDFClin Exp Dent Res
February 2025
School of Dentistry, Mashhad University of Medical Sciences, Mashhad, Iran.
Background And Objective: Tongue squamous cell carcinoma (TSCC) is the most prevalent oral cancer. Despite considerable advancements in treatment, the 5-year survival rate remains relatively unchanged. Langerhans cells (LCs) play an important role in antitumor immunity.
View Article and Find Full Text PDFJ Oral Pathol Med
January 2025
Gene Regulation in Cancer Group, Institute of Molecular Genetics and Genetic Engineering, Belgrade, Serbia.
Introduction: A recent pan-cancer transcriptome analysis indicated differential activity of alternative promoters of genes TNS3 and LRRFIP1 in head and neck squamous cell carcinoma compared to non-cancerous tissue. The promoters upregulated in head and neck squamous cell carcinoma regulate expression of transcripts TNS3-203 and LRRFIP1-211.
Objective: Our aim was to investigate the biomarker potential of TNS3-203 and LRRFIP1-211 transcripts in oral cancer, the most common type of head and neck cancer.
Pharmacol Res Perspect
February 2025
Sumitomo Pharma Switzerland GmbH, Basel, Switzerland.
Relugolix is an oral gonadotropin-releasing hormone receptor antagonist that suppresses sex steroid hormones and is approved as monotherapy for prostate cancer and as a fixed-dose combination with estradiol/norethindrone for the treatment of endometriosis and uterine fibroids. The aim of this postmarketing study was to determine the pharmacokinetics and quantify the amount of relugolix excreted into breast milk of healthy lactating women. Following a single, oral dose of 40 mg relugolix, breast milk was sampled over 120 h.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!